Ben Rosenbluth

Ben Rosenbluth is a PhD candidate in Bioengineering at Stanford with expertise in protein engineering, genome editing, and drug delivery. He joined Modi Ventures in 2023, where he invests primarily in therapeutics. Prior to Modi, Ben co-founded Detect, one of three companies to receive FDA authorization for an over-the-counter COVID-19 molecular test, which sold hundreds of thousands of units and raised over $110M in funding. Before Detect, he co-founded a gene editing company developing full-length gene insertion tools to treat monogenic liver diseases, and previously worked as a Scientist at Quantum-Si developing single-molecule sequencing technologies. Ben has advised early-stage biotech companies and venture funds in technical and strategic roles, and brings company-building experience across therapeutics, diagnostics, and enabling platforms. He received his B.S. in Engineering Sciences from Yale University.